BCP
KZR

Berylson Capital Partners’s Kezar Life Sciences KZR Stock Holding History

Berylson Capital Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,500
Closed -$424K – 24
2019
Q2 		$424K Hold
5,500
– – 0.76% 19
2019
Q1 		$976K Buy
+5,500
New +$1.08M 1.15% 30

Other funds holding KZR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Berylson Capital Partners's KZR Position: Q3 2019 in Review

Berylson Capital Partners sold out of Kezar Life Sciences (KZR) in Q3 2019, closing a stake of 5,500 shares — an estimated $424K sold.

Berylson Capital Partners first reported a position in KZR in Q1 2019 and held it in 2 quarters. The position peaked at $976K in Q1 2019. 54 funds tracked by Wall St. Rank hold KZR as of Q3 2019.

  • Berylson Capital Partners reported no remaining Kezar Life Sciences position as of Q3 2019 after selling out during the quarter.
  • Berylson Capital Partners sold 5,500 Kezar Life Sciences shares in Q3 2019, an estimated $424K.
  • Berylson Capital Partners first reported a position in Kezar Life Sciences in Q1 2019 and held it in 2 quarters.
  • Berylson Capital Partners's Kezar Life Sciences position peaked at $976K in Q1 2019.
  • 54 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2019.

Based on Berylson Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.